Highlights•Patients with advanced or recurrent mucinous ovarian carcinoma exhibit poor response to chemotherapy and poor prognosis.•We report marked response to carboplatin/paclitaxel/trastuzumab in recurrentERBB2-amplified mucinous ovarian carcinoma.•This case supports routine assessment of HER2 status in patients with advanced or recurrent mucinous ovarian carcinoma.